Chris Bennett Community Town Hall + Fundraiser · Mobilize

Join us for a community town hall and fundraiser as we kick off our 2026 leg of the Bennett for Congress Campaign. We will feature local community members speaking, an open Q&A with Chris, and space to learn more about our campaign. We’ll gather to connect, organize, and build momentum together for the exciting road ahead. Enjoy food, music, and good company as we raise the resources needed to power our people-centered campaign. All are welcome, come be part of the movement and bring a friend!

CD Private Equity Fund III share price

CD Private Equity Fund III (ASX:CD3) is an asset listed on the ASX, and part of the ETF sector. Grafa’s asset page shows CD Private Equity Fund III’s share pric

Howard G. Smith MD, AM on Instagram: "Nasal Spray Blunts Traumatic Brain Injury So say neurologists at Harvard’s Brigham and Women’s Hospital. In a mouse model, they show that a nasal spray containing an anti-CD3 monoclonal antibody significantly reduces brain inflammation and speeds recovery after a traumatic brain injury (TBI). This antibody, sprayed into the nasal cavities, activates regulatory T cells, Tregs, that then travel to the brain and release IL-10 that in turn reduces microglial-medial inflammation there. This anti-CD3 nasal spray must still prove its effectiveness in humans. If so, it will become a treatment for the TBI that follows concussions, motor vehicle accidents, and other sports-related head trauma. https://www.nature.com/articles/s41593-025-01877-7 #traumaticbraininjury #tbi #sports #cd3 #treg #il10 #mva #nasalspray"

0 likes, 0 comments - drhowardsmithreports on March 11, 2025: "Nasal Spray Blunts Traumatic Brain Injury So say neurologists at Harvard’s Brigham and Women’s Hospital. In a mouse model, they show that a nasal spray containing an anti-CD3 monoclonal antibody significantly reduces brain inflammation and speeds recovery after a traumatic brain injury (TBI). This antibody, sprayed into the nasal cavities, activates regulatory T cells, Tregs, that then travel to the brain and release IL-10 that in turn reduces microglial-medial inflammation there. This anti-CD3 nasal spray must still prove its effectiveness in humans. If so, it will become a treatment for the TBI that follows concussions, motor vehicle accidents, and other sports-related head trauma. https://www.nature.com/articles/s41593-025-01877-7 #traumaticbraininjury #tbi #sports #cd3 #treg #il10 #mva #nasalspray".

My Moviesadisummerlin.mp4

My Moviesadisummerlin.mp4

UCLA-led study uses base editing to correct mutation that causes rare immune deficiency

Advanced genome editing technology